BioSpace News Archive

Verisante Technology, Inc. is pleased to announce that further to its news release of June 30, 2022, it has received TSX-V acceptance and closed a proposed private placement for $98,580.00 for 9,858,000 common shares at a price of $0.01.

The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company”, “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to report its second quarter fiscal year 2022 financial results for the period ended May 31, 2022.

Novavax, Inc. (Nasdaq: NVAX), today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and over.

On July 13, 2022, Triastek, Inc. (“Triastek”) announced a collaboration with Eli Lilly and Company (“Lilly”), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract.

Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirms its guidance for its financial year 2022 after delivering a solid second quarter in line with plan.

Orion and MSD announce global collaboration for the development and commercialisation ofODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer

Pluristem Therapeutics Inc., a leading biotechnology company, announced topline results from its multinational double-blind, placebo-controlled phase III study.

BIOLASE, Inc., the global leader in dental lasers, announced a pilot program with Einstein Healthcare Network’s residency in General Dentistry to train General Dentist residents in the use of Waterlase dental laser technology.

Nuvalent, Inc. announced it will present two posters for its parallel lead programs, NVL-655, an ALK-selective inhibitor and NVL-520, a ROS1-selective inhibitor, at the IASLC 2022 World Conference on Lung Cancer Annual Meeting taking place August 6-9, 2022 in Vienna, Austria.

Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on using MeMed BV® in the Emergency Department to rapidly differentiate bacterial and viral infections.